A method for treating a cancer which overexpresses any of N-myc genes, C-myc genes and/or L-myc genes in a mammalian body, the method comprising:

administering a composition to the mammalian body, wherein the composition comprises at least one from the group consisting of taurolidine; taurultam; taurinamide; methylene glycol; taurultam and taurinamide in a ratio of 1 taurultam:7 taurinamide; and taurultam, taurinamide and methylene glycol in a ratio of 1 taurultam:7 taurinamide:1 methylene glycol.

An abuse deterrent pharmaceutical composition including a drug susceptible to abuse, a first acid soluble ingredient, a first buffering ingredient, and a delayed release buffering component.

A method for fabricating an oral drug delivery system includes steps as follows. A mixture is provided, which includes an organic ligand, a metal ion, a biological macromolecule and water. A coating step is performed for forming a biomimetic mineralized carrier encapsulated the biological macromolecule having a surface with the positive charge. A first solution including the biomimetic mineralized carrier is provided. A second solution including a yeast capsule is provided, wherein the yeast capsule has a surface with the negative charge. A loading step is performing, wherein the first solution is mixed with the second solution and then shaken for a shaking time, and the biomimetic mineralized carrier is loaded into the yeast capsule by an electrostatic force to form the oral drug delivery system.

The present invention relates to a granular pharmaceutical composition obtained by coating a nucleus with: (1) a layer containing a material having a damp-proofing function, and (2) a drug layer containing linaclotide, a pharmaceutically acceptable salt, or a hydrate thereof, and (3) a layer containing a material having a damp-proofing function. Also, the present invention relates to a method for manufacturing the granular pharmaceutical composition obtained by coating the nucleus with (1) the layer containing the material having a damp-proofing function, (2) the drug layer containing the linaclotide, the pharmaceutically acceptable salt, or the hydrate thereof, and (3) the layer containing the material having a damp-proofing function.

Methods of modulating peroxisome proliterator-activated receptor β (PPARβ) activity in a cell in a subject in need thereof are provided. The methods include administering an effective amount of a PPAPβ ligand to the subject where the PPAPβ ligand is selected from 1,3-Di-tertbutyl benzene (DBB), 2,4-Di-tertbutyl phenol (DBP), Methyl palmitate (MePA), 2,6-Di-tertbutyl-4-Methyl Phenol (DBMP), 3,4-Di-tertbutyl-Phenol (3,4-DBP), 2,3-Di-tertbutyl-Phenol (2,3-DBP), and 2,6-Di-tertbutyl-Phenol (2,6-DBP).

The present disclosure provides phospholipid-containing compounds, pharmaceutical compositions and microspheres that exhibit high affinity for mineralized metals. The present disclosure also provides strategies for using said compounds, compositions and microspheres in the treatment of nephrolithiasis or kidney stone disease, and methods of manufacturing and preparing said compounds and compositions.

Pharmaceutical formulation comprising centanafadine or a pharmaceutically acceptable salt thereof and an excipient, and related methods of manufacture and use, are disclosed.

Invention pertains to a free-flowing particulate powder including 2-90 wt. % of an active compound on a carrier, wherein the carrier has a D(v,0.1) of at least 100 microns, with the active compound being selected from lactylate in accordance with formula (1), Formula (1): R2-COO—[—CH(CH3)-COO]n-R1 or a Na, K, Ca, Mg, Fe(II), Zn, NH4, or Cu(II) salt thereof, a glycolylate of formula (2), Formula (2): R2-COO—[—CH2-COO]n-R1 or a Na, K, Ca, Mg, Fe(II), Zn, NH4, or Cu(II) salt thereof a lactate ester of formula (3), Formula (3): HO—CH(CH3)-COO—R2 and/or a glycolic acid ester of formula (4), Formula (4): HO—CH2-COO—R2 wherein in the above formulae R1 is selected from H, n stands for an integer with a value of 1-10, and R2 stands for a C1-C35 alkyl or alkenyl chain which may be branched or unbranched. The powder allows easy provision of the active compound to feed compositions.

A method of treating cancer by natural traditional Chinese medicine with sustained release and its preparation method thereof, includes the steps of: administrating a composition of traditional Chinese medicine, wherein the composition contains active ingredients of: ginsenoside, Astragalus polysaccharide, zedoary (Curcuma zedoaria), river bulrush (Sparganium stoloniferum Buch.-Ham), Ternstroemia gymnanthera, Fructus ligustri lucidi, licorice, Chinese skullcap (Scutellaria baicalnsis Georgi), Sculellaria barbata, paclitaxel, Silybum marianum (L.) Gaertn., and Cannabidiol (CBD). The composition can restore body balance and promote self-recovery. The composition can be used as an alternative medicine or can be used in combination with conventional cancer treatment, and is especially target for patients suffered from toxic side effects of radiotherapy and chemotherapy, which can increase the efficiency and reduce the toxicity of conventional cancer treatment and eliminate side effects of vomiting, hair loss, and unbearable soreness of the body.

A carrier free nanoparticle formulation with good circulation stability is made for anticancer drug delivery. Nanocrystals crystalized in the medium containing Pluronic F-127 then coated with albumin (Cim-F-Alb) had the smallest size and the most native albumin, and showed most favorable cell interaction profiles and better stability than commercial albumin based Abraxane formulation, while maintaining comparable cytotoxicity to those of Abraxane and solvent-dissolved paclitaxel (PTX).